Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan Sells 4,000 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Free Report) CFO Timothy Eugene Sullivan sold 4,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, April 1st. The shares were sold at an average price of $58.66, for a total value of $234,640.00. Following the transaction, the chief financial officer now owns 93,338 shares of the company’s stock, valued at approximately $5,475,207.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

  • On Friday, March 1st, Timothy Eugene Sullivan sold 6,000 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $63.22, for a total value of $379,320.00.
  • On Monday, February 12th, Timothy Eugene Sullivan sold 1,431 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $67.77, for a total value of $96,978.87.
  • On Monday, January 22nd, Timothy Eugene Sullivan sold 3,551 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $65.00, for a total value of $230,815.00.
  • On Tuesday, January 16th, Timothy Eugene Sullivan sold 2,235 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $66.81, for a total value of $149,320.35.

Apellis Pharmaceuticals Trading Down 6.7 %

APLS opened at $55.70 on Wednesday. The stock has a market cap of $6.72 billion, a price-to-earnings ratio of -12.43 and a beta of 0.88. The stock’s 50 day moving average price is $63.04 and its 200-day moving average price is $56.34. Apellis Pharmaceuticals, Inc. has a one year low of $19.83 and a one year high of $94.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, meeting analysts’ consensus estimates of ($0.73). The firm had revenue of $146.38 million for the quarter, compared to analysts’ expectations of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company’s quarterly revenue was up 545.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.50) earnings per share. On average, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.36 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of APLS. First Horizon Advisors Inc. grew its stake in shares of Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after buying an additional 265 shares during the last quarter. Covestor Ltd grew its stake in Apellis Pharmaceuticals by 564.2% in the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after purchasing an additional 677 shares in the last quarter. Stephens Consulting LLC bought a new position in Apellis Pharmaceuticals in the third quarter worth approximately $38,000. US Bancorp DE grew its stake in Apellis Pharmaceuticals by 391.2% in the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after purchasing an additional 884 shares in the last quarter. Finally, KBC Group NV bought a new position in Apellis Pharmaceuticals in the fourth quarter worth approximately $97,000. Institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on APLS shares. Raymond James upped their price objective on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 11th. Oppenheimer boosted their target price on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. boosted their target price on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Citigroup decreased their target price on Apellis Pharmaceuticals from $70.00 to $67.00 and set a “buy” rating on the stock in a research report on Friday, December 15th. Finally, The Goldman Sachs Group boosted their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $77.93.

Get Our Latest Stock Analysis on APLS

About Apellis Pharmaceuticals

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Recommended Stories

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.